

## **Stock Market announcement**

*Bergen, Norway – October 20, 2020:* The Norwegian listed company Lifecare AS (LIFE-ME) has a 25% ownership in the German company Digital Diagnostics AG, which has developed an accurate and reliable rapid test for Covid-19.

Bionovate Technologies Corp. (BIIO), a swiss based company traded at Nasdaq OTC Foreign, has announced a Share Exchange Agreement between Evergreen Solutions Ltd. and Human Data AG to the United States Securities and Exchange Commission.

According to the announcement Human Data AG will, in exchange for 25% of the shares in Digital Diagnostics AG, receive 54,270,000 shares in Bionovate Technologies Corp. from Evergreen Solutions Ltd.

Shares in Bionovate Technologies Corp. was traded at a price per share USD 4 on October 19<sup>th</sup>, 2020, valuating the transaction of 25% of Digital Diagnostics AG to USD 217,080,000.

In the opinion of Lifecare, the transaction is subject for board approval in Digital Diagnostics AG. Digital Diagnostics AG has not been notified of the transaction, and the transaction is not registered in the German Trade Register.

*Lifecare (LIFE-ME) is a Bergen-based technology company developing a miniature sensor for correct and continuous monitoring of diabetics' blood sugar. Its patented technology is also used as a central component in a rapid test for Covid-19 and as a measurement unit for reading out different biomarkers.*

For more information, please contact:

Joacim Holter

CEO, Lifecare

joacim.holter@lifecare.no

+47 40 05 90 40